SUMMARY The serum concentration of lipids and composition of fatty acids after overnight fasting were studied in 18 patients with rheumatoid arthritis treated for 12 weeks with either 20 ml of evening primrose oil containing 9% of y-linolenic acid or olive oil. The serum concentrations of oleic acid, eicosapentaenoic acid, and apolipoprotein B decreased and those of linoleic acid, y-linolenic acid, dihomo-y-linolenic acid, and arachidonic acid increased during treatment with evening primrose oil. During olive oil treatment the serum concentration of eicosapentaenoic acid decreased and those of high density lipoprotein-cholesterol and apolipoprotein A-I increased slightly. The decrease in serum eicosapentaenoic acid and the increase in arachidonic acid concentrations induced by evening primrose oil may not be favourable effects in patients with rheumatoid arthritis in the light of the roles of these fatty acids as precursors of eicosanoids.
Evening primrose oil (EPO) is currently one of the most popular unorthodox remedies for rheumatoid arthritis (RA). The rationale of its therapeutic use is based on the high amount (9%) of y-linolenic acid, which is metabolised into dihomo-y-linolenic acid, the natural precursor of the 1-series prostaglandins containing one double bond. Prostaglandins of the 1-series have been shown to possess antiinflammatory activity in experimental animal models.' By replacing arachidonic acid, precursor of the proinflammatory prostaglandins of the 2-series, as a substrate for cyclo-oxygenase, dietary ylinolenic acid has been thought to have a beneficial effect on the prostaglandin synthesis in RA.
Controlled studies on EPO in man have been carried out in atopic eczema,2 in Sj6gren's syndrome,3 and in RA. 4 5 No clinical effect or change in plasma or urinary prostaglandin E1, cAMP, or cGMP concentrations was noted during 12 weeks of treatment with EPO. 4 The recent report of Belch et al showed no improvement in the objective markers of inflammation, but the subjective response of the patients to EPO was better than that to olive oil. We carried out a double blind study in 20 patients with RA, using EPO and olive oil. No differences were noted between the two treatment groups in clinical signs, laboratory indicators of inflammatory activity, or plasma prostanoid concentrations (Jantti J, unpublished results). We now report changes in the serum lipids of these patients treated for 12 weeks with either EPO or olive oil.
Patients and methods
Twenty patients with definite or classical RA, willing to participate in the study, and accepting the 13 weeks minimum of absolute abstinence from nonsteroidal anti-inflammatory drugs (NSAIDs), were randomly allocated into two treatment groups of 10 patients each. The treatment was either olive oil 10 ml twice daily or evening primrose oil 10 ml twice daily. The oils were packed in numbered identical bottles, and the code was not broken until all the analyses had been carried out. The oils were supplied by Bio-Oil Research Ltd, Crewe, England. Evening primrose oil and serum lipids in RA 125 cholesterol, high density lipoprotein (HDL)-cholesterol, and triglycerides were studied according to the hospital routine on the same day as the sample was taken.
For fatty acid analysis serum lipids were extracted with chloroform-methanol (1:1) and saponified with KOH-ethanol. The fatty acids were methylated with HCl-methanol and analysed in a Hewlett-Packard 5880A gas chromatograph using an open tubular quartz capillary column of OV-351 (Nordion Instruments, Ltd, Finland) and a splitless injection technique. The temperature was programmed from 100°t o 240°C. Peaks generated by a flame ionisation detector were measured with a Hewlett-Packard electronic integrator. The results were expressed as percentages of the total area of all peaks from 14:0 to 22:6.
Results Tables 2 and 3 show the mean values (SD) of serum cholesterol, HDL-cholesterol, triglycerides, apolipoproteins A-I and B, and fatty acids in the two treatment groups. As expected, EPO significantly increased the proportion of linoleic acid, y-linolenic acid, and dihomo-y-linolenic acid, whereas olive oil had no effect on these fatty acids. EPO also increased the percentage of arachidonic acid, though the rise reached only marginal significance after six weeks. The main displaced fatty acid in the EPO treated group was oleic acid, but EPO also highly significantly decreased the percentage of eicosapentaenoic acid after six weeks, and still more after 12 weeks. Olive oil also decreased eicosapentaenoic acid after 12 weeks. The percentages of fFour patients.
the serum fatty acids did not differ significantly between the two groups before treatment. After 12 weeks the oleic acid level was lower (p<0-001), the y-linolenic and dihomo-y-linolenic acid values were higher (p<0001), and the arachidonic acid content was higher (p<0.01) in patients treated with EPO than in patients treated with olive oil (t test for unpaired values). Serum total cholesterol and triglyceride concentrations did not change in either of the groups, but the serum HDL-cholesterol concentration increased slightly during olive oil treatment. EPO had no effect on the serum concentration of apolipoprotein A-I, whereas that of apolipoprotein B decreased in all three patients studied. Apolipoprotein A-I increased in all four studied patients treated with olive oil, whereas apolipoprotein B decreased in three patients.
Discussion
EPO increased the proportion of y-linolenic and dihomo-y-linolenic acids in serum fatty acids as expected, but it also increased the proportion of arachidonic acid and decreased that of eicosapentaenoic acid. This is in accordance with earlier results,7 and is probably due to competition with the high proportion of w6 fatty acids, linoleate and ylinoleate in EPO for the enzymes metabolising polyunsaturated fatty acids, including eicosapentaenoic acid.
As y-linolenic and dihomo-y-linolenic acids are precursors of the 1-series prostaglandins, which have anti-inflammatory properties, the observed increase of these fatty acids in serum lipids can be regarded as a favourable effect. On the other hand, as arachidonic acid is the precursor of proinflammatory prostaglandins of the 2-series and leucotrienes of the 4-series its observed increase in serum lipids as a result of EPO treatment could potentially be harmful. Raised arachidonic acid levels may explain the higher concentrations of thromboxane B2 in five out of nine patients with RA treated with EPO, though the prostaglandin E2 concentrations in plasma showed no significant changes (Jantti J, unpublished results).
Eicosapentaenoic acid is a precursor of the biologically less active prostaglandins of the 3-series. It may even possess anti-inflammatory effects by inhibiting the 5-lipoxygenase pathway in neutrophils and monocytes and by antagonising the leucotriene B4 mediated functions of neutrophils.8 Treatment of RA with eicosapentaenoic acid has given promising though not excellent results.9 10 In addition, this acid has several favourable cardiovascular effects in man.1 Thus the observed decrease in the proportion of eicosapentaenoic acid in the plasma fatty acids can be regarded as unfavourable. Whether these theoretical suggestions are clinically relevant is not known, but they make EPO a questionable treatment for RA.
The total serum cholesterol concentrations in patients with active RA are lower than those of healthy people. In patients treated with slow acting antirheumatic drugs the low serum cholesterol values increase towards normal, whereas the NSAIDs have no effect.12 Most of our patients received slow acting antirheumatic drugs, but still their serum cholesterol concentrations were rather low. The treatments did not influence the total cholesterol, though olive oil administration slightly increased the HDL-cholesterol and apolipoprotein A-I concentrations in serum. It has been shown earlier that polyunsaturated fatty acids in diet decrease both the total and the HDL-cholesterol concentrations, whereas oleic acid decreases only the total cholesterol value.13 As HDL-cholesterol and apolipoprotein A-I are negative risk factors for coronary heart disease olive oil appears to have more favourable effect than EPO in regard to this disease.
It can be concluded that during treatment of RA for 12 weeks with evening primrose oil significant changes took place in the serum fatty acids. Some of these changes are theoretically undesirable in the light of the role of these fatty acids as precursors of prostaglandins and leucotrienes. 
